obesityHarbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity betHarbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform. more ➔
Boehringer IngelheimCooperationMillions for Preclinical Immunology: Boehringer Teams Up with ImmunitasGerman Boehringer Ingelheim is doubling down on next-generation autoimmune therapies with a deal worth up to €407.5m for a preclinical Immunitas (USA) antibody programme. The agreement highlights the … more ➔
artificial intelligenceIsomorphic Labs raises $2.1B for AI-enabled drug discovery driveIsomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform. more ➔
Venture CapitalInfex raises £4.3M for anti-infective R&D ahead of Phase 2a data on lead assetInfex Therapeutics has raised £4.3 million (€4.95 million) to advance an anti-infective pipeline led by a midphase drug candidate. more ➔
obesityEktaH links novel obesity drug to fat loss, muscle retention in early-phase trialEktaH has shared early clinical trial data on its first-in-class approach to treating obesity, encouraging the biotech to aim to advance the program into Phase 2 in the first half of next year. more ➔
AITolemy Bio raises €1.4m to build AI control panel for cell biologyCambridge-based Tolemy Bio has raised €1.4m in pre-seed financing to develop Orbit, an AI-native platform designed to help biopharma teams interpret, optimise and control cell-based therapeutic pr … more ➔
M&AAngelini inks $4.1B Catalyst takeover to fuel US expansionItaly’s Angelini Pharma has struck a deal to buy Catalyst Pharmaceuticals for $4.1 billion (€3.5 billion) to enter the US market. more ➔
InflaRx InflammationInflaRx attracts strong investor interest with US share offering turning to kidneyAs Amgen’s competing therapy has come under growing regulatory scrutiny, an opportunity has emerged for InflaRx N.V. to position its own oral C5aR inhibitor in the market. The Jena-based biotech company … more ➔
Venture CapitalScarlet raises £3.2 million to advance lab-grown red blood cell therapiesScarlet Therapeutics has raised £3.2 million (€3.7 million) to take therapies based on red blood cells (RBCs) to in vivo proof of concept, building on evidence that natural and lab-grown cells have … more ➔
BayerBayerFor several billions: Bayer adds Perfuse Therapeutics to portfolio of eye therapiesBayer AG is strengthening its ophthalmology portfolio with the acquisition of Perfuse Therapeutics for up to $2.45bn. The focus is on a Phase II candidate for glaucoma and diabetic retinopathy with potential … more ➔
Boehringer Ingelheim
InflaRx 
Bayer